Bristol Myers Squibb (CELG-RI) Cash from Investing Activities (2009 - 2026)

Bristol Myers Squibb has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$131.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 73.75% year-over-year to -$131.0 million; the TTM figure through Mar 2026 stood at -$3.8 billion (down 68.56% YoY), while the FY2025 annual figure was -$4.1 billion, up 80.65% from the prior year.
• Cash from Investing Activities improved to -$131.0 million in Q1 2026, from -$1.5 billion in the prior quarter.
• Over the last five years, Cash from Investing Activities for CELG-RI reached as high as $1.2 billion in Q4 2022 and fell as low as -$19.6 billion in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$410.0 million (2023), against an average of -$1.7 billion.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 202.49% — and 2024, when it plunged 9241.9%.
• A 5-year view of Cash from Investing Activities shows it stood at $1.2 billion in 2022, then sank by 210.96% to -$1.3 billion in 2023, then jumped by 85.44% to -$196.0 million in 2024, then plunged by 643.88% to -$1.5 billion in 2025, then jumped by 91.02% to -$131.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$131.0 million, -$1.5 billion, and -$1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.